After Seagen announced the accelerated approval of Tukysa in combination with Herceptin in second-line and later unresectable or metastatic colorectal cancer, or mCRC, William Blair analyst Andy Hsieh noted that the label allows the possibility of treating patients as early as second-line and called it "broader-than-expected." While the commercial opportunity for this approval is "modest," he believes the expansion into HER2-positive indications beyond breast cancer is "a worthwhile endeavor" and represents a "modest growth opportunity." Hsieh reiterates an Outperform rating on Seagen shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGEN:
- Seagen announces FDA accelerated approval of TUKYSA-trastuzumab combo
- Pieris Pharmaceuticals announces $5M milestone from Seagen
- Seagen, Astellas and Merck announce FDA acceptance of sBLA in urothelial cancer
- Astellas, Seagen, and Merck announce priority review for Padcev and Keytruda
- Seagen announces results from Phase 2 trial of ADCETRIS